Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Omalizumab in idiopathic anaphylaxis.

× No keyword cloud information.

17 in total

Review 1. Pathogenesis, newly recognized etiologies, and management of idiopathic anaphylaxis.

Authors: James L Kuhlen; Yamini V Virkud
Journal: Discov Med Date: 2015-02 Impact factor: 2.970

Review 2. Exercise-Induced Anaphylaxis: Literature Review and Recent Updates.

Authors: Matthew P Giannetti
Journal: Curr Allergy Asthma Rep Date: 2018-10-26 Impact factor: 4.806

3. New insights into the utility of omalizumab.

Authors: Juan Carlos Cardet; Thomas B Casale
Journal: J Allergy Clin Immunol Date: 2019-01-26 Impact factor: 10.793

Review 4. Use of omalizumab in the treatment of food allergy and anaphylaxis.

Authors: Jay A Lieberman; Mirna Chehade
Journal: Curr Allergy Asthma Rep Date: 2013-02 Impact factor: 4.806

5. World allergy organization guidelines for the assessment and management of anaphylaxis.

Authors: F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal: World Allergy Organ J Date: 2011-02-23 Impact factor: 4.084

Review 6. Management and Prevention of Anaphylaxis.

Authors: Anne-Marie Irani; Elias G Akl
Journal: F1000Res Date: 2015-12-22

7. Exercise-induced anaphylaxis: a case report and review of the diagnosis and treatment of a rare but potentially life-threatening syndrome.

Authors: Nathan T Jaqua; Matthew R Peterson; Karla L Davis
Journal: Case Rep Med Date: 2013-03-27

8. Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors: Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal: Drug Des Devel Ther Date: 2014-02-07 Impact factor: 4.162

9. Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report.

Authors: Iwona Stelmach; Anna Sztafińska; Katarzyna Woicka-Kolejwa; Joanna Jerzyńska
Journal: Postepy Dermatol Alergol Date: 2014-06-13 Impact factor: 1.837

10. Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy.

Authors: Jaechun Lee
Journal: Asia Pac Allergy Date: 2014-04-29